Iyer Roshni, Hsia Connie C W, Nguyen Kytai T
Department of Bioengineering, University of Texas at Arlington, 500 UTA Blvd, ERB 241, Arlington, TX 76019.
Curr Pharm Des. 2015;21(36):5233-44. doi: 10.2174/1381612821666150923095742.
Inhalation of aerosolized compounds is a popular, non-invasive route for the targeted delivery of therapeutic molecules to the lung. Various types of nanoparticles have been used as carriers to facilitate drug uptake and intracellular action in order to treat lung diseases and/or to facilitate lung repair and growth. These include polymeric nanoparticles, liposomes, and dendrimers, among many others. In addition, nanoparticles are sometimes used in combination with small molecules, cytokines, growth factors, and/or pluripotent stem cells. Here we review the rationale and state-of-the-art nanotechnology for pulmonary drug delivery, with particular attention to new technological developments and approaches as well as the challenges associated with them, the emerging advances, and opportunities for future development in this field.
吸入雾化化合物是一种将治疗性分子靶向递送至肺部的常用非侵入性途径。各种类型的纳米颗粒已被用作载体，以促进药物摄取和细胞内作用，从而治疗肺部疾病和/或促进肺修复与生长。其中包括聚合物纳米颗粒、脂质体和树枝状大分子等。此外，纳米颗粒有时还与小分子、细胞因子、生长因子和/或多能干细胞联合使用。在此，我们综述了用于肺部药物递送的原理和前沿纳米技术，特别关注新技术发展与方法以及与之相关的挑战、新兴进展和该领域未来发展的机遇。
